Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
NCT07399171Phase 2Recruiting
- Sponsor
- Halia Therapeutics
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Study Arm HT-4253 with Study Arm Placebo (2 arms). Primary endpoint: Transition from positive, high risk APS2 score to negative, low risk APS2 score at 48 weeks. Started May 2026; status: recruiting.
02
Drugs
HT-4253
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07399171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399171.